How to lead a research team from #hackathon to plenary in 6 months
…continue reading the full story in The Cancer Letter and Q&A with Matthew Ong
Feature image credit: The Cancer Letter
Similar Posts
Economic Roots of COVID-19 Racial Inequities
COVID-19 disparities persist in our most vulnerable communities, including low-income families and racial and ethnic minorities, partly because of the financial necessity to continue working, as well as the lack of employment opportunities that enable their residents to work remotely. They are more likely to be essential workers, and that increases their exposure to the…
Doctoral Dissertation Defense
An Invitation Please join us at my doctoral dissertation defense titled “Mathematical Models to Evaluate the Clinical and Economic Impact of Biomedical HIV Prevention Strategies in the United States” at 12:30 pm on Thursday, May 3, 2018 at the Washington Research Foundation (WRF) Data Science Studio on the 6th floor of the Physics/Astronomy Tower at the University of Washington…
Meeting the President of the European Central Bank
This is the story of how I met the most powerful man in the European Union and found my picture with him in a German newspaper. Mario Draghi, President of the European Central Bank, attended the Lindau Nobel Laureate Meeting to deliver a keynote address to hundreds of Ph.D. Economics students (including me) and 19…
The next generation of ISPOR leadership
It has been a privilege to serve and represent more than 5,000 health economics graduate students in 77 countries and support the work of presidents from 107 student chapters during my term as Chair of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Student Network in 2017-2018. Where We Are Today I continue to be…
Do FDA Alerts Impact Practice Patterns?
Think about the last time you were forced to make a decision in the face of uncertainty. You may have been choosing which job offer to accept or whether to move from renting to buying a home. You probably weighed the tradeoffs and asked yourself whether it made sense to gather additional information or to…
data|evidence|policy|practice
The Irish Department of Health (DoH) is in the process of developing a national biosimilar medicines policy which aims to increase biosimilar use by creating a robust framework where biologicals and biosimilars can be used safely, cost-effectively, and confidently in the health service. In this example from an Irish teaching hospital, the introduction of the biosimilar first to new patients, along with a switching study executed in parallel, helped to raise prescriber confidence.
